Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 6, 2011, Pages 409-414

  Khorana, N ^a   Maphanta, S ^a   Lohitnavy, O ^a   Srichaiya, A ^a   Sayasathid, J ^a  

^a NARESUAN UNIVERSITY   (Thailand)

Author keywords

9 hydroxyrisperidone; Bioequivalence; HPLC UV; Pharmacokinetics; Risperidone

Indexed keywords

RISPERIDONE; RISPERIDONE GPO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; THAILAND;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; HUMANS; MALE; RISPERIDONE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 79959483133     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201509     Document Type: Article

References (15)

1. Meltzer H. Y. Chapter 58. Mechanism of action of atypical antipsychotic drugs. In: Davis KL, Charney D, Coyle JT and Nemeroff C (eds). Neuropsychopharmacology, The fifth Generation of Progress, Lippincott Williams & Wilkins, Philadelphia, USA; 2002. p. 819-831.
2. Stathis P, Antoniou K, Papadopoulou-Daifotis Z, Rimikis MN, Varonos D. Risperidone: a novel antipsychotic with many "atypical" properties? Psychopharmacology (Berl). 1996; 127: 181-186.
3. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000; 68: 29-39.
4. Fang J, Bourin M, Baker G. B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. N-S Arch Pharmacol. 1999; 359: 147-151.
5. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994; 114: 566-572. (Pubitemid 24152136)
6. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAI, Zylicz Z, Visscher HW, Jonkman JHG. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993; 54: 257-268.
7. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993; 21: 1134-1141.
8. Thailand Food and Drug Administration. Guideline for the conduct of bioavailability and bioequivalence studies. Drug Control Division. Ministry of Public Health, Thailand, 2001.
9. Avenoso A, Facciolà G, Salemi M, Spina E. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000; 746: 173-181. (Pubitemid 30657933)
10. US Food and Drug Administration. Guideline for industry: Bioavailability and bioequivalence studies for administered drug products-general considerations. Center for Drug Evaluation and Research. Rockville, MD, 2000.
11. Mahatthanatrakul W, Nontaput T, Sriwiriyajan S, Ridtitid W, Wongnawa M. Bioequivalence study of a generic risperidone (Iperdal®) in healthy Thai male volunteers. Songklanakarin J Sci Technol. 2008; 50: 307-312.
12. Huang MZ, Shentu JZ, Chen JC, Liu J, Zhou HL. Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers. J Zhejiang Univ Sci B. 2008; 9: 114-120. (Pubitemid 351234297)
13. Cho HY, Lee YB. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res. 2006; 29: 525-533.
14. Patterson S, Jones B, eds. Bioequivalence and Statistics in Clinical Pharmacology, Chapman & Hall/CRC, Taylor & Francis Group, Boca Raton; USA, 2006. p. 47.
15. Asean Guidelines. Guidelines for the conduct of Bioavailability and Bioequivalence Studies. Adopted from Note for Guidance on the Investigation of Bioavailability and Bioequivalence (The European Agency for the Evaluation of Medicinal Products, London, 2001) with some adaptation for Asean application, 2004.